Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02626780 · ClinicalTrials.gov registry record · NA
Adipose-derived SVF for Treatment of Alopecia
A NA study, sponsored by GID BIO.
- Completed
- Registry status
- NA
- Development phase
- 7
- Enrollment target
NCT02626780: Completed NA study, sponsored by GID BIO.
NCT02626780 is a NA study that has completed, run by GID BIO. The registered enrollment target is 7 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02626780, a NA study, has completed, sponsored by GID BIO.
- COMPLETED
- Registry status
- NA
- Development phase
- 7 participants
- Enrollment target
Study Summary
The general objective of this study is to conduct a safety and feasibility study of a single injection of autologous adipose-derived SVF for the treatment of alopecia.
Primary Outcome
Subjects will be monitored for Adverse events for the duration of the study.
Interventions
- DEVICE GID SVF-2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2016-07-20 |
| Est. Completion | 2017-01-22 |
| Phase | NA |
What the finished NCT02626780 record still lists
NCT02626780 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 1 intervention - of which GID SVF-2 is the first listed.
NCT02626780 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02626780 about?
NCT02626780 is a clinical study titled "Adipose-derived SVF for Treatment of Alopecia". The general objective of this study is to conduct a safety and feasibility study of a single injection of autologous adipose-derived SVF for the treatment of alopecia.
What is the current status of trial NCT02626780?
This trial is currently completed. It is a NA study. The enrollment target is 7 participants. The study started on 2016-07-20. Estimated completion is 2017-01-22.
What interventions are being tested in trial NCT02626780?
The interventions under investigation include: GID SVF-2 (DEVICE).
Who is sponsoring clinical trial NCT02626780?
This trial is sponsored by GID BIO, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02626780's enrollment target sits among peer trials
7 1982nd of 2000 higher than 18 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI